NeuCyte, Inc. is a leading neuroscience drug discovery company based in Sunnyvale, CA. They have developed a proprietary in vitro platform, utilizing their SynFire technology, for generating human induced pluripotent stem cell (iPSC)-derived induced neural cells. With a focus on improving the lives of patients suffering from neurological disorders, NeuCyte is actively pursuing drug discovery programs for conditions such as Fragile X Syndrome, Epilepsy, and ALS.
Through a license agreement with Boston Children's Hospital, NeuCyte has granted the hospital a non-exclusive license to manufacture transcription factor Ngn2 programmed induced neurons. This technology will be used for internal research, teaching, educational purposes, and to provide services to other academic institutions. With their expertise and dedication to advancing human health, NeuCyte aims to create a tool that closely resembles human biology in vitro, making it an important asset in the field of neuroscience research.
Generated from the website